Kivizidiale (Timolol, Travoprost)

Timolol, a non‑selective beta‑blocker, decreases the production of aqueous humour by blocking β‑adrenergic receptors in the ciliary body. Travoprost, a prostaglandin F2α analogue, enhances uveoscleral outflow of aqueous humour. The dual mechanism provides a complementary reduction in intra‑ocular pressure.

The dosing regimen for Kivizidiale is determined by the prescribing ophthalmologist. Typically, one drop is instilled in the affected eye(s) once daily in the evening, but the exact dose and timing should follow the clinician’s instructions.

The safety of Kivizidiale in pregnancy or while breastfeeding has not been fully established. Healthcare providers should weigh the potential benefits against possible risks and consider alternative treatments if appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with single‑component agents, Kivizidiale offers a combined mechanism—reduced aqueous production and increased outflow—potentially achieving greater intra‑ocular pressure reduction. This may reduce the need for multiple separate drops, improving adherence, but individual response varies and should be assessed by the ophthalmologist.

Kivizidiale should be stored at room temperature, below 25 °C, in its original packaging. Keep the bottle tightly closed, protect it from light and moisture, and discard any solution that appears discolored or contains particles.

Kivizidiale is applied as an eye drop. The patient should wash hands, tilt the head back, pull down the lower eyelid to form a pocket, and instill one drop into the conjunctival sac of the prescribed eye(s). Close the eye gently for a few seconds without blinking excessively.

Serious risks include severe allergic reactions, marked worsening of glaucoma, systemic bradycardia or hypotension, and bronchospasm, especially in patients with pre‑existing respiratory disease. Any sudden vision changes, chest discomfort, or breathing difficulties should prompt immediate medical attention.

Kivizidiale is contraindicated in patients with known hypersensitivity to timolol, travoprost, or any excipients in the formulation. It should also be avoided in individuals with severe sinus bradycardia, second‑ or third‑degree heart block, uncontrolled asthma, or active ocular infections without prior medical clearance.